Neuroimaging and the search for a cure for Alzheimer disease

Radiology

Volumn 269, Issue 3, 2013, Pages 671-691

  Petrella, Jeffrey R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; FLORBETABEN; FLORBETAPIR F 18; FLUMETANOL; FLUORINE 18; RADIOPHARMACEUTICAL AGENT; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; APP GENE; BRAIN ATROPHY; DEGENERATIVE DISEASE; GENE; HUMAN; INCIDENCE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NONHUMAN; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; RADIOLOGIST; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; NEUROIMAGING;

EID: 84890032037     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.13122503     Document Type: Review

References (104)

1. Haub C. World population aging: clocks illustrate growth in population under age 5 and over age 65. Population Bulletin. http://www.prb.org/Articles/ 2011/agingpopulationclocks.aspx. Published 2011.
2. Wimo A, Prince M. World Alzheimer Report 2010: The Global Economic Impact of Dementia. London, England: Alzheimer's Disease International, 2010.
3. Petrella JR, Doraiswamy PM. Alzheimer's disease: 100 years of progress. Neuroimaging Clin N Am 2005;15(4):xiii-xiv.
4. Ballenger JF. Self, Senility, and Alzheimer's Disease in Modern America: A History. Baltimore, Md: The Johns Hopkins University Press, 2006.
5. Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift fur Psychiatrie und phychish-Gerichtliche Medizin 1907;64:146-148.
6. Alzheimer A. A unique illness involving the cerebral cortex. In: Rothenberg DA, Hochberg FH, eds. Neurological Classics in Modern Translation. London, England: Hafner, 1977;41-43.
7. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012;8(1):1-13.
8. Katzman R. The prevalence and malignancy of Alzheimer disease: a major killer (editorial). Arch Neurol 1976;33(4):217-218.
9. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau: a component of Alzheimer paired helical filaments. J Biol Chem 1986;261(13):6084-6089.
10. Kosik KS, Joachim CL, Selkoe DJ. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A 1986;83(11):4044-4048.
11. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 1985;82(12):4245-4249.
12. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82(4):239-259.
13. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997;18(4): 351-357.
14. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297(5580):353- 356.
15. Goldgaber D, Lerman MI, McBride OW, Saffiotti U, Gajdusek DC. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science 1987;235(4791):877-880.
16. Tanzi RE, Gusella JF, Watkins PC, et al. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 1987;235(4791): 880-884.
17. Robakis NK, Ramakrishna N, Wolfe G, Wisniewski HM. Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides. Proc Natl Acad Sci U S A 1987;84(12):4190-4194.
18. St George-Hyslop PH, Tanzi RE, Polinsky RJ, et al. The genetic defect causing familial Alzheimer's disease maps on chromosome. Science 1987;235(4791):885-890.
19. Borchelt DR, Thinakaran G, Eckman CB, et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 1996; 17(5):1005-1013.
20. Citron M, Westaway D, Xia W, et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid betaprotein in both transfected cells and transgenic mice. Nat Med 1997;3(1):67-72.
21. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996;2(8):864-870.
22. Duff K, Eckman C, Zehr C, et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 1996; 383(6602):710-713.
23. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256(5054):184-185.
24. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 1991;6(4): 487-498.
25. Dong S, Duan Y, Hu Y, Zhao Z. Advances in the pathogenesis of Alzheimer's disease: a re-evaluation of amyloid cascade hypothesis. Transl Neurodegener 2012;1(1):18.
26. Duan Y, Dong S, Gu F, Hu Y, Zhao Z. Advances in the pathogenesis of Alzheimer's disease: focusing on tau-mediated neurodegeneration. Transl Neurodegener 2012; 1(1):24.
27. Hardy J. The relationship between amyloid and tau. J Mol Neurosci 2003;20(2):203-206.
28. Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013;12(2):207-216.
29. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9(1):119-128.
30. Bartus RT, Dean RL 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217(4558): 408-414.
31. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999;66(2):137-147.
32. Krall WJ, Sramek JJ, Cutler NR. Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease. Ann Pharmacother 1999;33(4):441-450.
33. Giacobini E. Invited review: cholinesterase inhibitors for Alzheimer's disease therapy-from tacrine to future applications. Neurochem Int 1998;32(5-6):413-419.
34. Lleó A, Greenberg SM, Growdon JH. Current pharmacotherapy for Alzheimer's disease. Annu Rev Med 2006;57:513-533.
35. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's dis ease with Pittsburgh compound-B. Ann Neurol 2004;55(3):306-319.
36. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006;59(3):512-519.
37. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67(3):446-452.
38. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in nondemented individuals: evidence for preclinical Alzheimer's disease. Brain 2007;130(Pt 11): 2837-2844.
39. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007;68(20):1718-1725.
40. Patterson JC 2nd, Mosley ML. How available is positron emission tomography in the United States? Mol Imaging Biol 2005; 7(3):197-200.
41. Seibyl J, Zubal IG, Jennings D, Marek K, Doraiswamy PM. Molecular PET imaging in multicenter Alzheimer's therapeutic trials: current trends and implementation strategies. Expert Rev Neurother 2011;11(12): 1783-1793.
42. Yang L, Rieves D, Ganley C. Brain amyloid imaging: FDA approval of florbetapir F18 injection. N Engl J Med 2012;367(10):885-887.
43. Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging betaamyloid pathology. JAMA 2011;305(3): 275-283.
44. Shoghi-Jadid K, Small GW, Agdeppa ED, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002;10(1):24-35.
45. Small GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006;355(25): 2652-2663.
46. Tolboom N, van der Flier WM, Yaqub M, et al. Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment. Neurology 2009;73(24):2079-2085.
47. Fodero-Tavoletti MT, Okamura N, Furumoto S, et al. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain 2011;134(Pt 4):1089-1100.
48. Jack CR Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009; 132(Pt 5):1355-1365.
49. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367(9):795-804.
50. Haas C. Strategies, development, and pitfalls of therapeutic options for Alzheimer's disease. J Alzheimers Dis 2012;28(2):241-281.
51. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebocontrolled, ascending-dose study. Lancet Neurol 2010;9(4):363-372.
52. Doody RS. Phase 3 Studies of Solanezumab for Mild to Moderate Alzheimer's Disease. In: Proceedings of the137th annual meeting of the American Neurological Association. Boston, Mass: American Neurological Association, 2012.
53. Castellani RJ, Lee HG, Siedlak SL, et al. Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta. J Alzheimers Dis 2009;18(2):447-452.
54. Lee HG, Casadesus G, Zhu X, Takeda A, Perry G, Smith MA. Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer disease. Ann N Y Acad Sci 2004;1019:1-4.
55. Sperling RA, Jack CR Jr, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med 2011;3(111):111cm33.
56. Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 2008;192(1):106-113.
57. Whitwell JL, Josephs KA, Murray ME, et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 2008;71(10):743-749.
58. Jack CR Jr, Bentley MD, Twomey CK, Zinsmeister AR. MR imaging-based volume measurements of the hippocampal formation and anterior temporal lobe: validation studies. Radiology 1990;176(1):205-209.
59. Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002;33(3):341-355.
60. Fischl B, van der Kouwe A, Destrieux C, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex 2004;14(1):11-22.
61. Jack CR Jr, Barkhof F, Bernstein MA, et al. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement 2011;7(4):474, e4.
62. Carrillo MC, Bain LJ, Frisoni GB, Weiner MW. Worldwide Alzheimer's disease neuroimaging initiative. Alzheimers Dement 2012;8(4):337-342.
63. Cui Y, Liu B, Luo S, et al. Identification of conversion from mild cognitive impairment to Alzheimer's disease using multivariate predictors. PLoS ONE 2011;6(7):e21896.
64. Davatzikos C, Bhatt P, Shaw LM, Batmanghelich KN, Trojanowski JQ. Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification. Neurobiol Aging 2011;32(12):e19-e27.
65. Ewers M, Walsh C, Trojanowski JQ, et al. Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging 2012;33(7):1203-1214.
66. Gomar JJ, Bobes-Bascaran MT, Conejero-Goldberg C, Davies P, Goldberg TE; Alzheimer's Disease Neuroimaging Initiative. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. Arch Gen Psychiatry 2011;68(9):961-969.
67. Hinrichs C, Singh V, Mukherjee L, et al. Spatially augmented LPboosting for AD classification with evaluations on the ADNI dataset. Neuroimage 2009;48(1):138-149.
68. Kohannim O, Hua X, Hibar DP, et al. Boosting power for clinical trials using classifiers based on multiple biomarkers. Neurobiol Aging 2010;31(8):1429-1442.
69. Shaffer JL, Petrella JR, Sheldon FC, et al. Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology 2013;266(2): 583-591.
70. Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 2009;73(4):294-301.
71. Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 2009; 73(4):287-293.
72. Walhovd KB, Fjell AM, Brewer J, et al. Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer dis ease. AJNR Am J Neuroradiol 2010; 31(2):347-354.
73. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7(3):270-279.
74. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7(3):263-269.
75. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7(3):280-292.
76. Selkoe DJ. Resolving controversies on the path to Alzheimer's therapeutics. Nat Med 2011;17(9):1060-1065.
77. Petrella JR, Prince SE, Krishnan S, Husn H, Kelley L, Doraiswamy PM. Effects of donepezil on cortical activation in mild cognitive impairment: a pilot double-blind placebo-controlled trial using functional MR imaging. AJNR Am J Neuroradiol 2009; 30(2):411-416.
78. Dickerson BC, Sperling RA. Neuroimaging biomarkers for clinical trials of diseasemodifying therapies in Alzheimer's disease. NeuroRx 2005;2(2):348-360.
79. Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. J Nucl Med 2013;54(3):476-490.
80. Moghbel MC, Saboury B, Basu S, et al. Amyloid-b imaging with PET in Alzheimer's disease: is it feasible with current radiotracers and technologies? Eur J Nucl Med Mol Imaging 2012;39(2):202-208.
81. Doraiswamy PM, Sperling RA, Coleman RE, et al. Amyloid-b assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology 2012;79(16): 1636-1644.
82. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008;29(10):1456-1465.
83. Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11CPIB PET study. Neurology 2009;73(10): 754-760.
84. Gurol ME, Dierksen G, Betensky R, et al. Predicting sites of new hemorrhage with amyloid imaging in cerebral amyloid angiopathy. Neurology 2012;79(4):320-326.
85. Sperling RA, Jack CR Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 2011;7(4):367-385.
86. Buckler AJ, Bresolin L, Dunnick NR, Sullivan DC; Group. A collaborative enterprise for multi-stakeholder participation in the advancement of quantitative imaging. Radiology 2011;258(3):906-914.
87. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002;298(5594):789-791.
88. Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default mode of brain function. Proc Natl Acad Sci U S A 2001;98(2):676-682.
89. Hedden T, Van Dijk KR, Becker JA, et al. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci 2009;29(40): 12686-12694.
90. Petrella JR, Sheldon FC, Prince SE, Calhoun VD, Doraiswamy PM. Default mode network connectivity in stable vs progressive mild cognitive impairment. Neurology 2011;76(6):511-517.
91. Sperling RA, Laviolette PS, O'Keefe K, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 2009; 63(2):178-188.
92. Buckner RL, Andrews-Hanna JR, Schacter DL. The brain's default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci 2008;1124:1-38.
93. Petrella JR, Wang L, Krishnan S, et al. Cortical deactivation in mild cognitive impairment: high-field-strength functional MR imaging. Radiology 2007;245(1):224-235. [Published correction appears in Radiology 2008;246(1):338.]
94. Sheline YI, Raichle ME, Snyder AZ, et al. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry 2010; 67(6):584-587.
95. Wang J, Zuo X, Dai Z, et al. Disrupted functional brain connectome in individuals at risk for Alzheimer's disease. Biol Psychiatry 2013;73(5):472-481.
96. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25(34):7709-7717.
97. Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron 2009;62(1):42-52.
98. Zhou J, Gennatas ED, Kramer JH, Miller BL, Seeley WW. Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron 2012;73(6): 1216-1227.
99. Prusiner SB. Molecular biology of prion diseases. Science 1991;252(5012):1515-1522.
100. Liu L, Drouet V, Wu JW, et al. Trans-synaptic spread of tau pathology in vivo. PLoS ONE 2012;7(2):e31302.
101. Mott RT, Hulette CM. Neuropathology of Alzheimer's disease. Neuroimaging Clin N Am 2005;15(4):755-765, ix.
102. Salloway S, Ferris S, Kluger A, et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology 2004;63(4):651-657.
103. Holland D, Brewer JB, Hagler DJ, Fennema-Notestine C, Dale AM. Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A 2009;106(49):20954-20959.
104. Ryan R. Update on Alzheimer's Disease Clinical Trials. National Institute on Aging. https://www.alz.washington.edu/NONMEMBER/SPR12/Ryan.pdf. Published April 2012.